Welcome to our dedicated page for Smith & Nephew plc news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew plc stock.
Smith & Nephew plc, also known as Smith+Nephew, is a leading British multinational medical equipment manufacturing company headquartered in Watford, England. Established in 1856, this pioneering firm excels in designing, manufacturing, and marketing advanced medical devices and technologies. Their core business areas include orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.
Smith+Nephew's revenue is diversified across three main segments: Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%). The United States contributes roughly half of the company’s total revenue, with other developed markets accounting for over 30%, and the remaining portion coming from emerging markets. The company operates in more than 100 countries and generated annual sales of $5.2 billion in 2022.
Recently, Smith+Nephew celebrated a significant milestone by receiving 510(k) clearance from the U.S. FDA for the AETOS Shoulder System. This advanced system is designed to enhance surgical experiences through greater intraoperative flexibility and fewer conversion steps and instruments, simplifying the operating room flow. The AETOS Shoulder System is part of the company's expanding Upper Extremity portfolio and complements its market-leading Sports Medicine shoulder repair and biologics solutions.
Another notable achievement includes the standout results of the REGENETEN Bioinductive Implant from a randomized controlled trial. This innovative implant substantially reduced re-tear rates in rotator cuff repairs, showcasing Smith+Nephew's commitment to improving patient outcomes through evidence-based solutions.
Smith+Nephew has also entered into a groundbreaking Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This agreement allows for collaborative research across all business units, fostering innovation and enhancing combat casualty care.
Moreover, the company launched the RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US, which is a patient-centric option for treating chronic wounds. This system is designed for easy portability and quiet operation, making it suitable for patients' daily activities.
Smith+Nephew's purpose, 'Life Unlimited,' reflects their mission to help restore people's bodies and self-belief by using technology to enhance living. With 19,000 dedicated employees, the company continues to innovate and improve the quality of life for patients worldwide.
For more information about Smith+Nephew, please visit their official website and follow them on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.
Smith+Nephew (LSE:SN, NYSE:SNN) announces ECRI's upgraded 'favorable' Evidence Bar ratings for their ALLEVYN LIFE Sacrum Foam Dressings and LEAF Patient Monitoring System in pressure injury prevention. The ALLEVYN LIFE Sacrum Foam Dressing features a multilayer design for managing chronic and acute wounds, while the LEAF System is a wireless solution improving turn protocol adherence up to 98% and reducing hospital-acquired pressure injuries odds by 73%.
The LEAF System has demonstrated improved nursing efficiencies and generated up to $1.8 million estimated annual cost savings in one facility's critical care units. Hospital-acquired pressure injuries cost an estimated 60,000 lives and $26.8 billion in the US annually. These ratings strengthen Smith+Nephew's position in pressure injury prevention solutions.
Smith+Nephew (LSE:SN, NYSE:SNN) announces FDA clearance for CORIOGRAPH Pre-Op Planning and Modeling Services for total hip arthroplasty (THA). This innovative planning software, exclusive to CORI Surgical System users, enables both X-ray and CT scan planning for patient-specific outcomes.
The system leverages 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans. Key features include advanced modeling capabilities with patient-specific spinopelvic classification, image-agnostic planning with 2D/3D images, and compatibility across Smith+Nephew's hip implant solutions.
The first procedures were completed at Orlando Health Jewett Orthopedic Institute, with surgeons reporting improved accuracy and optimization of component positioning.
Smith+Nephew (NYSE:SNN) has received FDA 510(k) clearance for its AETOS Stemless, a new stemless anatomic total shoulder implant. This addition expands the AETOS Shoulder System portfolio, which was introduced last year. The device features an inlay collar, cruciate fins, and porous titanium coating designed to encourage biological fixation and maximize stability.
The AETOS Stemless allows for streamlined convertibility from Stemless to Meta Stem, offering surgeons more flexibility in personalizing treatments. The system is cleared for use in the United States and approved in Canada, complementing Smith+Nephew's Sports Medicine shoulder repair and biologics solutions. Total shoulder arthroplasty is projected to reach 250,000 procedures annually in the US by 2025.
Smith+Nephew's RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System has won the Red Dot Award for Design Concept 2024 in the Medical Devices and Technology Category. This award recognizes its intuitive pairing of NPWT in a patient-friendly design. The system, launched in 2024, is designed for treating chronic wounds, which affect an estimated 8.2 million people in the US with an annual financial burden of $33 billion.
The RENASYS EDGE NPWT System is lightweight, compact, and quiet, allowing patients to easily carry or wear it without drawing attention to their condition. This design consideration is crucial, as 68% of patients with chronic wounds often become self-conscious and isolated. Smith+Nephew's focus on patient-centric design is further evidenced by their PICO◊ 14 NPWT System, which also won a Red Dot Award for Design Concept in 2021 for its portable and discreet design.
Smith+Nephew (LSE:SN, NYSE:SNN) has signed a co-marketing agreement with JointVue for its OrthoSonic™ 3D Surgery Planning Technology, the only ultrasound device currently on the market to deliver 3D preoperative planning. This technology will be used with Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty, allowing surgeons to create personalized surgical plans.
The combination offers an ideal solution for Ambulatory Surgery Centers (ASCs) where OR space is JointVue's technology provides a radiation-free, automated planning tool that generates a 3D plan within minutes, guiding surgeons to tailor procedures uniquely to each patient. This partnership expands the imaging modalities available to Smith+Nephew customers for pre-op robotic planning, potentially improving patient satisfaction and operating room efficiency.
Smith+Nephew has launched the LEGION Hinged Knee (HK) System with OXINIUM Technology in the United States. This system, part of the LEGION Total Knee System, is designed to provide a natural range of motion and allows surgeons to transition intraoperatively from a constrained revision knee implant to a hinged assembly. The OXINIUM Technology offers several advantages over traditional materials, including:
- Lower inflammatory response
- Superior wear resistance
- Reduced surface damage
- Fewer signs of corrosion damage
These benefits help mitigate common risk factors associated with revision procedures. The LEGION revision with OXINIUM Technology has demonstrated the lowest risk of re-revision compared to the class average.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced positive feedback from the first surgical cases using its new CATALYSTEM Primary Hip System. The system, designed for primary hip surgery, features a triple-taper stem design with uniform proximal loading and reduced distal stem geometry, making it ideal for anterior approach procedures. Key features include:
1. RI.HIP NAVIGATION for enhanced patient outcomes
2. Proprietary ACCUBROACH Technology for reproducible stem seating
3. User-friendly instruments suitable for direct anterior approach
4. Superior cutting and precise feel for rotational stability
Surgeons praised the system's precision, efficiency, and anatomical fit. The CATALYSTEM Primary Hip System represents a significant advancement in hip replacement technology, combining advanced technology with patient personalization.
Cadence, a leading provider of contract manufacturing solutions for MedTech and Pharma markets, has appointed Bob White to its Board of Directors. White brings over 25 years of business leadership experience, with a focus on operational excellence, technological innovation, and strategic growth. He previously served as Executive Vice President and Group President at Medtronic, managing five global businesses across 70 countries. White's experience includes:
- Leading 25,000 employees and 13 manufacturing facilities
- Achieving consistent above-market growth
- Completing seven acquisitions, a joint venture, and a multi-billion-dollar divestiture
White currently serves as an Independent Director for Smith & Nephew (NYSE: SNN) and holds an MBA from Case Western Reserve University. His appointment is expected to contribute significantly to Cadence's strategic goals and market approach.
Smith+Nephew (NYSE:SNN) has launched TOTAL ANKLE Patient-Matched Guides for total ankle replacement (TAR) procedures. This innovative system, developed in partnership with 3D Systems, offers surgeons a predictable and efficient option for planning and performing TAR. Key benefits include:
1. Predictability in the OR with integrated fluoroscopic cues and all-in-one instrumentation
2. Accuracy to plan through fluoroscopic alignment cues and standard instrumentation
3. User-friendly design providing tactile feedback and precise patient fit
The guides are compatible with Smith+Nephew's CADENCE and SALTO TALARIS Total Ankle Systems. This launch strengthens the company's position in the growing TAR market, which is expected to see a CAGR of 6.98% through 2031.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.
The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.
InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.
FAQ
What is the current stock price of Smith & Nephew plc (SNN)?
What is the market cap of Smith & Nephew plc (SNN)?
What does Smith & Nephew specialize in?
Where is Smith & Nephew headquartered?
What are the main revenue segments of Smith & Nephew?
What recent achievement has Smith & Nephew made in orthopedic technology?
How does the REGENETEN Bioinductive Implant benefit patients?
What is the purpose of Smith & Nephew's Master CRADA with the USAISR?
What is unique about the RENASYS EDGE NPWT System?
What is Smith & Nephew's company mission?
How many countries does Smith & Nephew operate in?
How can I learn more about Smith & Nephew?
